



PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

Manuscript NO: 40616

Title: Treatment approach to type 2 diabetes: Past, present and future

Reviewer's code: 02823579

Reviewer's country: United States

Science editor: Ruo-Yu Ma

Date sent for review: 2018-09-12

Date reviewed: 2018-09-13

Review time: 22 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

good narrative of the treatment history of diabetes however bariatric surgery for the T2DM and BMI >35 should be mentioned, in accordance with ADA 2016 guidelines

INITIAL REVIEW OF THE MANUSCRIPT



Baishideng Publishing Group

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<https://www.wjgnet.com>

Google Search:

The same title

Duplicate publication

Plagiarism

No

BPG Search:

The same title

Duplicate publication

Plagiarism

No



PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

Manuscript NO: 40616

Title: Treatment approach to type 2 diabetes: Past, present and future

Reviewer's code: 00597793

Reviewer's country: United States

Science editor: Ruo-Yu Ma

Date sent for review: 2018-09-12

Date reviewed: 2018-09-16

Review time: 4 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This is a fine review. My comments are mostly technical. 1. Title - I am not so sure that "future" developments in DM is correct. You do not discuss glucagon blockers, adiponectin agonists, and other such medications. You may want to stick to "Past & Present". 2. Abstract "..has risen from biguanides.." you mean has "progressed from.."



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

3. Core Tip - "Throw" is "through"..... The idea of aggressive reduction of glucose not leading to improved CVD mortality comes out of nowhere and does not fit well with everything you have said until now. The follow up ACCORD study showed reduced MIs with improved glycemic control. So you may wish to say that expansion of glucose lowering options has lead to improvements in CVD but an exclusively glucose-centric approach to diabetes most likely will not lead to any further reductions in CVD mortality - or something like that. 4. History - "it was not recognized at a disease until 1812 when the NEJM was founded" - are you saying the first time DM was defined as a disease was in the NEJM or it was defined as disease in 1812? Clarify please. 5. "This type of DM is phenotypically often accompanied by central OBESITY, ..." 6. "...nature course of disease" should be "natural course of disease" 7. Legend to Figure - "...which is why the metabolomics insulin effects" - I do not understand this. Rewrite. 8. In several places you write "till" - use "until" 9. "...finally obtained by R DeFronzo.." - should be "described" 10. The pharmacological treatment options...several years ago - actually it was 60 years ago! 11. The section on future developments does not talk about future treatments. It is more a summary of the present. Either delete this section or actually discuss new approaches.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- [] The same title
- [] Duplicate publication
- [] Plagiarism
- [Y] No

BPG Search:



Baishideng Publishing Group

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

- The same title
- Duplicate publication
- Plagiarism
- No